La médula ósea es el tejido donde se producen las células de la sangre mediante un proceso denominado hematopoyesis. Con la edad, este proceso se desequilibra y aumenta la producción de células de la línea mieloide, como neutrófilos y monocitos, mient …
Descubren una clave oculta de la inflamación asociada al envejecimiento Read More »
La enfermedad de Dent es una enfermedad renal minoritaria causada por alteraciones genéticas que afectan al funcionamiento del túbulo proximal del riñón. En aproximadamente un 60% de los casos, la patología está causada por mutaciones en el gen CLCN5, que co …
Hallazgo sobre la variabilidad de la enfermedad de Dent Read More »
Employed doctors report worse well-being than independent practitioners, with workload and administrative burden driving distress, according to a new survey.
Mental health gap widens between employed and independent physicians: survey Read More »
The multi-drug partnership with Orbis Medicines—which Novo has backed since the biotech’s seed rounds—is focused on cardiometabolic targets, but the technology at the center of the deal could deliver oral weight loss candidates. Obesity rival Eli Lilly has also helped fund Orbis.
Widely adopted in open and laparoscopic surgeries, the LigaSure instrument is now available for use with the Hugo robotic system.
FDA clears vessel-sealing device for Medtronic’s Hugo robot Read More »
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
After Novartis’ devastating M&A losses, long live the executive willing to try Read More »
While increases in the interest rate from the Federal Reserve are usually bad for biotech, the sector at this moment is poised to withstand the blow, according to analysts, though earlier stage companies may be left in the lurch.
Fed rate hike won’t hold biotech down despite climbing capital costs Read More »
Learn what manufacturing challenges lie ahead, how to equip your team to protect your program from avoidable manufacturing and regulatory setbacks and forge partnerships that can withstand the next five years of industry turbulence.
The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
Roche bets up to $1B to advance next-gen bispecifics with Dualitas Read More »
With just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a strategic review after the failure of a cardiovascular study.
Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial Read More »
